Cubist Systematic Strategies LLC Sells 132,107 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Cubist Systematic Strategies LLC decreased its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 40.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 198,373 shares of the biopharmaceutical company’s stock after selling 132,107 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.37% of Emergent BioSolutions worth $1,896,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Invesco Ltd. increased its position in Emergent BioSolutions by 70.9% during the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after purchasing an additional 638,995 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after purchasing an additional 444,790 shares in the last quarter. American Century Companies Inc. increased its position in Emergent BioSolutions by 23.4% during the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after purchasing an additional 404,667 shares in the last quarter. Trexquant Investment LP increased its position in Emergent BioSolutions by 59.3% during the 4th quarter. Trexquant Investment LP now owns 701,517 shares of the biopharmaceutical company’s stock worth $6,707,000 after purchasing an additional 261,099 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in Emergent BioSolutions during the 4th quarter worth approximately $1,831,000. Institutional investors own 78.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EBS. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st.

Insider Activity at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. This trade represents a 25.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is currently owned by company insiders.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $5.68 on Monday. The firm has a market cap of $308.63 million, a PE ratio of -1.39 and a beta of 2.09. The firm’s fifty day moving average is $5.14 and its 200-day moving average is $7.90. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a 52 week low of $4.02 and a 52 week high of $15.10.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.49 by $0.22. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $222.20 million for the quarter, compared to analysts’ expectations of $218.50 million. Sell-side analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions declared that its board has initiated a share repurchase program on Monday, March 31st that allows the company to buyback $50.00 million in outstanding shares. This buyback authorization allows the biopharmaceutical company to repurchase up to 19% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.